Among the patients with contra-lateral lung metastasis harboring EGFR mutation, there were 182 patients enrolled in the outcome statistical analysis with EGFR-TKI prescription as initial systemic therapy, including 54 patients with miliary lung metastasis and 128 patients with non-miliary lung metastasis. Here, EGFR is linked to metastasis.